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Abstract 21 
Background: It is suggested that immunosuppression due to transplantation might be a risk 22 
for human polyomavirus KI (KIPyV) and WU (WUPyV) infection. Most of the publications 23 
report data about stem cell transplant patients, little is known about these virus infections in 24 
renal transplant patients.   25 
 2 
Objectives: To study the presence of KIPyV and WUPyV in upper respiratory, plasma and 26 
urine samples from renal transplant patients. To analyse clinical and personal data. 27 
Study design: 532 respiratory, 503 plasma and 464 urine samples were collected from 77 28 
renal transplant patients. KIPyV and WUPyV were detected by nested and quantitative real-29 
time PCR. Patient and clinical data from medical records were analyzed. 30 
Results: KIPyV was detected in respiratory, plasma and urine samples from 14.3 %, 3.9 % 31 
and 4.1 % of renal transplant patients. WUPyV was found in respiratory and plasma 32 
specimens from 9.1 % and 5.3 % of the patients. Significant association was revealed between 33 
the detection of KIPyV and WUPyV and the time of samples collection and the age of the 34 
patients. KIPyV was presented in respiratory and plasma sample at the same time. KIPyV was 35 
detected in plasma samples from two patients and in urine samples of three other patients 36 
providing also KIPyV positive respiratory samples at the same time. No clinical consequences 37 
of KIPyV or WUPyV infection were found. 38 
Conclusion: Although no clinical consequences of KIPyV and WUPyV infections were found 39 
in renal transplant patients, it is suggested that renal transplantation might result in higher 40 
susceptibility or reactivation of these infection. 41 
 42 
 43 
 44 
 45 
1. Background 46 
KI and WU polyomaviruses (KIPyV and WUPyV) were discovered in respiratory 47 
samples from children suffering from respiratory symptoms in 2007 [1, 2].  Subsequent 48 
studies using PCR methods revealed the presence of viral DNA in many different samples: 49 
respiratory, blood, stool, cerebrospinal fluid, lymphoid tissue, lung [3] and urine samples [4, 50 
 3 
5]. Seroepidemiological studies showed that both viruses are widespread, the seropositivity of 51 
KIPyV and WUPyV are 55-100 % in the adult population [6-9]. Since similarly high 52 
seropositivity was also found among young children, it is suggested that primary infections by 53 
KI and WU viruses occur during childhood [6, 7]. This is also strengthened by the finding that 54 
the viruses were detected more frequently in samples from children [10]. Respiratory and/or 55 
fecal-oral transmission is suggested for both KI and WU viruses [11]. Despite the numerous 56 
prevalence data published, little is known about the pathogenesis of KIPyV and WUPyV, and 57 
none of them is associated with any disease. Primary infection by WU and KI viruses might 58 
be mild or asymptomatic. The higher prevalence in samples (respiratory samples, lymphoid 59 
tissues, blood and urine) from immunocompromised patients suggests that 60 
immunosuppression might result in higher susceptibility or reactivation of KIPyV and 61 
WUPyV [3-5, 12-15]. Transplantation associated with immunosuppression might be a risk for 62 
these infections, since higher frequencies of these viruses were found in stem cell transplant 63 
patients compared with other immunocompromised groups. Increased pathogenic potential 64 
was also suggested, even if not higher prevalence, but higher viral loads were detected in 65 
immunocompromised patients [16]. Most of these studies focused on haematopoietic cell 66 
transplant patients, and we published previously data about renal transplant patients [4].  67 
In this study we detected KIPyV in respiratory, blood and urine samples from renal 68 
transplant patients, frequency was 14.3, 3.9 and 4.1%. WUPyV was found in 9.1% of 69 
respiratory and 5.3% of blood samples. No clinical consequence was found. 70 
 71 
2. Objectives 72 
Based on the above mentioned data it is suggested that renal transplant patients 73 
receiving immunosuppressive therapy might be more susceptible for these infections or 74 
reactivation of these viruses may occur. To examine the prevalence of these viruses in renal 75 
 4 
transplant patients, to find potential site of viral replication and/or latency the presence of 76 
KIPyV and WUPyV was studied by PCR in respiratory, blood and urine samples from renal 77 
transplant patients from transplantation until 18 month. Clinical and personal data of the 78 
patients were analyzed to study the potential pathogenic role of KIPyV and WUPyV. 79 
 80 
3. Study design 81 
3.1. Patients and samples 82 
The study was approved by Regional and Institutional Ethics Committee of University 83 
of Debrecen. 84 
Throat swab, plasma (from EDTA blood samples) and urine samples were collected 85 
from 77 renal transplant patients receiving kidney between September 2008 and September 86 
2012 at University of Debrecen as described previously [4]. Samples were collected from 87 
patients visiting the outpatient clinic of the renal transplant centre at University of Debrecen. 88 
Table 1. summarizes the number of samples and the data of the patients. It was preferred to 89 
collect blood and urine sample together with respiratory samples at the same time, but beside 90 
532 respiratory samples, 503 plasma and 464 urine samples were provided.  Samples were 91 
collected 1-16 times from the following number of patients: 2, 10, 9, 3, 5, 3, 6, 9, 11, 9, 4, 2, 92 
1, 2, 1 patients at the 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 or 16 time points. 93 
Immediately after collection, nucleic acid was isolated from 200 µL of each sample 94 
using High Pure Viral Nucleic Acid Kit (Roche, Switzerland) according to the manufacturer’s 95 
instructions. DNA eluted in 50 µL volume was stored at -20 ºC until use.  96 
Clinical and laboratory data were obtained from medical records. 97 
 98 
3.2. Nested and real-time PCR for WUPyV and KIPyV 99 
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 Nested PCR was performed as described previously [17]. For quantitative detection of 100 
KIPyV and WUPyV DNA, multiplex real-time PCR (qPCR) was carried out with primers and 101 
probes published previously [14] in a final volume of 50 µL using TaqMan Universal PCR 102 
Master Mix in an Applied Biosystem 7500 real-time PCR instrument (Applied Biosystems, 103 
USA). Standard curves generated by PCR amplification of 10-fold dilutions of plasmids 104 
containing WU and KI polyomavirus DNA were used for absolute quantification. All samples 105 
were tested by nested and qPCR, 10 µL nucleic acid was amplified in each PCR. Nested PCR 106 
positivity was confirmed by sequencing if qPCR was negative. 107 
 108 
3.3. Statistical analysis 109 
Difference in frequency for categorical variables was analysed by Fisher’s exact and χ2 110 
test. For continuous variables Mann-Whitney test was applied. Logistic regression was used 111 
to analyze the relationship between KIPyV and/or WUPyV detection and different variables. 112 
Cox regression models were performed to analyse the risk factors for detection of KI or WU 113 
viruses, including age, month of examination, sex, CMV reactivation, respiratory symptoms, 114 
leukopaenia, monocytopaenia, neutropaenia, leukocytosis, monocytosis and neutrophilia. 115 
Analyses were performed using SigmaPlot version 10.0 (Systat Software, Inc., USA) and 116 
XLSTAT 2014 software (Addinsoft, USA) , p value < 0.05 was considered significant. 117 
 118 
4. Results 119 
In our study group 20.7 % of the renal transplant patients (16/77) provided KIPyV 120 
and/or WUPyV positive respiratory samples during the examination period. KIPyV DNA was 121 
detected in 17 respiratory samples (17/532; 3.2 %) taken from 11 patients (11/77; 14.3 %). 122 
Three patients had two or three positive respiratory samples within 7-21 days, and one patient 123 
provided a KIPyV positive sample 158 days after his first positive sample. WUPyV was 124 
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found in 8 respiratory samples (8/532; 1.5%) from 7 patients (7/77; 9.1%). Two WUPyV 125 
positive samples were collected within 14 days from one patient. Both viruses was detected in 126 
one sample at the same time (Table 2.). The frequency of KIPyV was significantly higher 127 
than that of WUPyV in positive respiratory samples (17/24 vs. 8/24; p=0.019). Only three 128 
respiratory samples were qPCR negative and nested PCR positive, but sequencing proved the 129 
presence of the polyomaviruses. Additionally, one of these patients had KIPyV qPCR positive 130 
plasma, and one provided KIPyV positive urine at the same time. Although KIPyV viral loads 131 
were higher in respiratory samples (range: 2.2E+02-1.04E+07 copies/mL; median: 1.39E+03 132 
copies/mL), it was not significant difference (p=0.056) comparing with WUPyV viral loads 133 
(range: 4.6E+02-2.18E+04 copies/mL; median: 7.31E+02 copies/mL). Significant difference 134 
was found regarding the sample collection time points between KI and/or WU viral DNA 135 
positive and negative samples (p=0.001; Table 2.).  Although the number of positive 136 
samples/patients is low, patients provided WUPyV positive respiratory samples mainly during 137 
summer (6/7), seasonality was not apparent for KIPyV (Figure 1.). Logistic regression 138 
showed significant relationship between the presence of KIPyV and/or WUPyV in respiratory 139 
samples and the age of the patients (odds ratio 0.963, 95% CI 0.935-0.991, p = 0.01)  Age was 140 
a significant risk factor for detecting KIPyV and/or WUPyV (hazard ratio 0.963 CI 0.936-141 
0.991 p=0.009). KIPyV was detected in samples from patients 20-59 years of age, while 142 
WUPyV was found also in respiratory samples from a patient < 20 years of age. All patients > 143 
60 years of age provided respiratory samples negative for KI and WU virus, respectively 144 
(Figure 2.). Most of the samples positive for KIPyV and WUPyV were collected 1-5 months 145 
after transplantation (Figure 3A), logistic regression significant relationship between the 146 
presence of KIPyV and/or WUPyV in respiratory samples and the time of sampling (odds 147 
ratio 0.992, 95% CI 0.988-0.996, p<0.001).. 148 
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Relationship between detection of KI and/or WU viruses in respiratory samples and 149 
sex, CMV reactivation, leukopaenia, monocytopaenia, neutropaenia, leukocytosis, 150 
monocytosis, neutrophilia was not revealed. Mild, upper respiratory symptoms were recorded 151 
only for three patients provided KIPyV/WUPyV positive respiratory samples, but similar 152 
symptoms were also existed when 26 negative samples were collected from patients (3/24 vs. 153 
26/508; p=0.11).  154 
Plasma samples were also collected together with the 19 respiratory samples positive 155 
for KIPyV and/or WUPyV from 13 patients. In two out of these 18 plasma samples KIPyV, 156 
and in one sample WUPyV was also detected, while the respiratory samples of these three 157 
patients were KIPyV positive. Therewith, in three additional plasmas out of the 503 samples 158 
WUPyV DNA was found, and in one of them KIPyV was also detected at the same time. The 159 
respiratory samples of these three patients were negative for viral DNA at that time point. 160 
Altogether, 7.9 % of the patients (6/76) had viraemia, the frequency of KIPyV and WUPyV 161 
was 0.6% and 0.8%, respectively (3/503 and 4/503). The viral loads were low, ≤ 260 copies 162 
/mL. Significant difference was found regarding the sample collection time points between KI 163 
and/or WU viral DNA positive and negative samples (p=0.006; Table 2.).  Figure 3B shows 164 
the time points of sampling for KIPyV and WUPyv positive samples. KIPyV and/or WUPyV 165 
viraemia was significantly more frequent in patients providing also positive respiratory 166 
sample at the same  time (3/19 vs. 3/484; p=0.0009). Logistic regression model found 167 
association between KIPyV/WUPyV viraemia and the presence of these viruses in respiratory 168 
samples at the same time (odds ratio 0.008 95 % CI 0.015-0.441, p=0.004). Not any other 169 
parameter (age, sex, CMV reactivation, leukopaenia, monocytopaenia, neutropaenia, 170 
leukocytosis, monocytosis, neutrophilia) was associated with KIPyv/WUPyV viraemia based 171 
on Cox regression model. 172 
 8 
At the time point of WU or KI viral DNA positive respiratory samples 6 patients 173 
provided also urine samples, out of which KIPyV was detected in three samples (3/11). All 174 
other urine samples were negative for KIPyV and WUPyV, the frequency  of KIPyV in urine 175 
samples was  0.6 % (3/464; Table 2.). Positivity was confirmed with sequencing of the nested 176 
PCR product. Viruria was revealed in 4.1 % of the patients, and viraemia was not detected at 177 
that time point. Figure 3C shows the time points of sampling. 178 
   179 
5. Discussion 180 
Previous studies with haematopoietic transplant patients suggest that 181 
immunosuppression related to transplantation may result in higher frequencies of KIPyV and 182 
WUPyV infection [14, 16, 18, 19]. At the same time, little is known about renal transplant 183 
patients [4]. In this study the presence of KIPyV and WUPyV was studied in upper 184 
respiratory tract, plasma and urine samples from 77 renal transplant patients from 185 
transplantation until 18 months after it. KIPyV was revealed in all sample types, WUPyV was 186 
found in respiratory and plasma samples. KIPyV was detected in respiratory samples from 187 
14.3 % of the patients, while 9.1 % of the patients provided WUPyV positive respiratory 188 
sample during this study. The frequency in respiratory samples was 3.2 % and 1.5 % for 189 
KIPyV and WUPyV, respectively.  KIPyV was detected in 0.8-17.8 % of respiratory 190 
specimens from stem cell transplant patients meaning 0.8-22 % KIPyV prevalence in these 191 
patients. Lower prevalence of WUPyV was reported, 0-7 % in stem cell transplant patients. 192 
[14, 16, 18, 19]. Our data from renal transplant patients are in accordance with these 193 
publications.  194 
We found that most of the KIPyV and WUPyV positive respiratory samples were 195 
provided 1-5 month after transplantation. The detection of the viruses was significantly 196 
associated with the time point of sample collection. All KIPyV positive respiratory samples 197 
 9 
were collected from patients at 21-44 years of age (median 29 years), while WUPyV was 198 
detected mainly in patients at 12-68 years of age (median 45 years), the difference was not 199 
statistically significant (p=0.058). Seroprevalence studies found high KIPyV and WUPyV 200 
seropositivity in young children similar to that of the adults suggesting that primary infections 201 
occur mainly during childhood [6, 7]. Additionally, in most of the publications higher PCR 202 
prevalence data for KIPyV and WUPyV were reported in respiratory samples compared with 203 
adults [3, 20, 21]. These findings suggest that the detected KIPyV and WUPyV infections 204 
might be reactivations or re-infections.  205 
Seasonality of KIPyV in respiratory samples was not found in this study. Although the 206 
number of the positive samples is low, most of the WUPyV positive samples were provided 207 
during summer. A previous study also found a small peak of WUPyV detection  during 208 
summer, however they found WUPyV throughout the year [22]. Further studies are required 209 
to determine whether seasonality of WUPyV occurs. 210 
In our study group respiratory symptoms were not associated with the detection of 211 
KIPyV and/or WUPyV in the upper respiratory specimens. Only three patients provided 212 
KIPyV (1 patient) or WUPyV (2 patients) positive respiratory samples had mild, upper 213 
respiratory symptom (coughing, sore throat without fever). Not any risk factor was associated 214 
with KIPyV/WUPyV detection, although the available clinical data were analysed (CMV 215 
reactivation, haematologic clinical data, symptoms of patients). 216 
 In a study high viral loads of KIPyV in respiratory samples from paediatric stem cell 217 
transplant patients were found suggesting higher pathological role for KI virus in these 218 
patients, but not for WUPyV [16]. In our study KIPyV was not only more frequent, but the 219 
viral loads also were higher then that of WUPyV in respiratory samples. Although the KIPyV 220 
viral loads in respiratory samples from our patients were lower then was detected in paediatric 221 
patients [16], it may refer to active viral replication.  222 
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We detected KIPyV and WUPyV in plasma samples from 3.9 % and 5.2 % of patients. 223 
Previous publications also reported that KIPyV and WUPyV can be detected in blood [22]. At 224 
the same time, in a study with stem cell transplant patients KIPyV and WUPyV was not 225 
detected in plasma samples suggesting that these viruses have no effect on post-transplant 226 
clinical course [23]. Recently, detection of KIPyV antigen in lung and spleen tissues has been 227 
published.  It was also determined that CD68+ cells in lung harbour KIPyV antigens, hence  228 
alveolar macrophages may be infected by KIPyV [24]. In our study we found co-existence of 229 
KIPyV in respiratory and blood specimen from two patients, and one patient provided KIPyV 230 
positive respiratory and WUPyV positive blood samples at the same time point. The viral 231 
loads in all plasma specimens were low, there is no evidence for active virus replication in 232 
blood circulation, but it also cannot be excluded. Blood cells might be the site of active 233 
infection, non productive infection, the site of latency, as it was hypothesized for CD68+ cells 234 
[24]. We detected KIPyV in urine samples from three patients provided also KIPyV positive 235 
respiratory specimen at the same time. Analysis of clinical data did not reveal any risk factor 236 
or association with clinical parameters. 237 
Different hypotheses arise from the co-detection of KIPyV in respiratory and blood or 238 
urine specimens. The respiratory tract infection may enter the blood circulation directly or by 239 
circulating blood derived cells, as was suggested [24]. By the blood circulation the virus can 240 
reach other organs, maybe kidney, urinary tract. It cannot be excluded that KIPyV/WUpyV 241 
detected in respiratory, blood and urine samples from adult, renal transplant patients 242 
originated from reactivation of latency, or latent infections (blood, urinary tract) were found, 243 
if these viruses are able to establish latency.  244 
In conclusion, we detected KIPyV and WUPyV in respiratory specimens from renal 245 
transplant patients with a frequency similar to published data about other 246 
immunocompromised patients. Age and the time point of sample collection were associated 247 
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with detection. KIPyV and WUPyV were also found in plasma samples, co-occurrence of 248 
KIPyV in blood and respiratory specimens were detected. Presence of KIPyV in urine 249 
samples were also revealed, these patients had KIPyV positive respiratory samples at the 250 
same time. No clinical consequences of KIPyV or WUPyV infection were found. Further 251 
studies are required to clarify many questions in connection with these viruses.  252 
  253 
Funding: 254 
The research is supported by the Hungarian Scientific Research Fund (OTKA-PD109108) and 255 
research activity of Eszter Csoma was supported by the European Union and the State of 256 
Hungary, co-financed by the European Social Fund in the framework of TÁMOP-4.2.4.A/ 2-257 
11/1-2012-0001 ‘National Excellence Program’. 258 
 259 
Competing interests: 260 
The authors have no competing interest. 261 
Ethical approval : 262 
The study was approved by Regional and Institutional Ethics Committee of University of 263 
Debrecen (number: 2740-2008, 2917-2009, IX-R-052/00876-2/2012). 264 
 265 
 References 266 
 267 
1. Allander T, Andreasson K, Gupta S, Bjerkner A, Bogdanovic G, Persson MA, et al. 268 
Identification of a third human polyomavirus. J Virol. 2007; 81: 4130-4136. 269 
2. Gaynor AM, Nissen MD, Whiley DM, Mackay IM, Lambert SB, Wu G, et al. 270 
Identification of a novel polyomavirus from patients with acute respiratory tract 271 
infections. PLoS Pathog. 2007; 3: e64. 272 
 12 
3. Babakir-Mina M, Ciccozzi M, Perno CF, Ciotti M. The human polyomaviruses KI and 273 
WU: virological background and clinical implications. Apmis. 2013; 121: 746-754. 274 
4. Csoma E, Meszaros B, Asztalos L, Konya J, Gergely L. Prevalence of WU and KI 275 
polyomaviruses in plasma, urine, and respiratory samples from renal transplant 276 
patients. J Med Virol. 2011; 83: 1275-1278. 277 
5. Motamedi N, Mairhofer H, Nitschko H, Jager G, Koszinowski UH. The polyomaviruses 278 
WUPyV and KIPyV: a retrospective quantitative analysis in patients undergoing 279 
hematopoietic stem cell transplantation. Virol J. 2012; 9: 209. 280 
6. Kean JM, Rao S, Wang M, Garcea RL. Seroepidemiology of human polyomaviruses. 281 
PLoS Pathog. 2009; 5: e1000363. 282 
7. Nguyen NL, Le BM, Wang D. Serologic evidence of frequent human infection with WU 283 
and KI polyomaviruses. Emerg Infect Dis. 2009; 15: 1199-1205. 284 
8. Neske F, Prifert C, Scheiner B, Ewald M, Schubert J, Opitz A, et al. High prevalence of 285 
antibodies against polyomavirus WU, polyomavirus KI, and human bocavirus in 286 
German blood donors. BMC Infect Dis. 2010; 10: 215. 287 
9. Miller MA, Weibel C, Kahn JS, Andiman WA. Seroepidemiology of WU polyomavirus 288 
among children exposed perinatally to HIV-1. J Med Virol. 2012; 84: 188-193. 289 
10. Dalianis T, Hirsch HH. Human polyomaviruses in disease and cancer. Virology. 2013; 290 
437: 63-72. 291 
11. Babakir-Mina M, Ciccozzi M, Perno CF, Ciotti M. The novel KI, WU, MC 292 
polyomaviruses: possible human pathogens? New Microbiol. 2011; 34: 1-8. 293 
12. Kantola K, Sadeghi M, Lahtinen A, Koskenvuo M, Aaltonen LM, Mottonen M, et al. 294 
Merkel cell polyomavirus DNA in tumor-free tonsillar tissues and upper respiratory 295 
tract samples: implications for respiratory transmission and latency. J Clin Virol. 2009; 296 
45: 292-295. 297 
 13 
13. Venter M, Visser A, Lassauniere R. Human polyomaviruses, WU and KI in HIV 298 
exposed children with acute lower respiratory tract infections in hospitals in South 299 
Africa. J Clin Virol. 2009; 44: 230-234. 300 
14. Kuypers J, Campbell AP, Guthrie KA, Wright NL, Englund JA, Corey L, et al. WU and 301 
KI polyomaviruses in respiratory samples from allogeneic hematopoietic cell transplant 302 
recipients. Emerg Infect Dis. 2012; 18: 1580-1588. 303 
15. Sharp CP, Norja P, Anthony I, Bell JE, Simmonds P. Reactivation and mutation of 304 
newly discovered WU, KI, and Merkel cell carcinoma polyomaviruses in 305 
immunosuppressed individuals. J Infect Dis. 2009; 199: 398-404. 306 
16. Rao S, Garcea RL, Robinson CC, Simoes EA. WU and KI polyomavirus infections in 307 
pediatric hematology/oncology patients with acute respiratory tract illness. J Clin Virol. 308 
2011; 52: 28-32. 309 
17. Csoma E, Sapy T, Meszaros B, Gergely L. Novel human polyomaviruses in pregnancy: 310 
higher prevalence of BKPyV, but no WUPyV, KIPyV and HPyV9. J Clin Virol. 2012; 55: 311 
262-265. 312 
18. Mourez T, Bergeron A, Ribaud P, Scieux C, de Latour RP, Tazi A, et al. Polyomaviruses 313 
KI and WU in immunocompromised patients with respiratory disease. Emerg Infect Dis. 314 
2009; 15: 107-109. 315 
19. Debiaggi M, Canducci F, Brerra R, Sampaolo M, Marinozzi MC, Parea M, et al. 316 
Molecular epidemiology of KI and WU polyomaviruses in infants with acute respiratory 317 
disease and in adult hematopoietic stem cell transplant recipients. J Med Virol. 2010; 82: 318 
153-156. 319 
20. Ren L, Gonzalez R, Xie Z, Zhang J, Liu C, Li J, et al. WU and KI polyomavirus present 320 
in the respiratory tract of children, but not in immunocompetent adults. J Clin Virol. 321 
2008; 43: 330-333. 322 
 14 
21. Abedi Kiasari B, Vallely PJ, Corless CE, Al-Hammadi M, Klapper PE. Age-related 323 
pattern of KI and WU polyomavirus infection. J Clin Virol. 2008; 43: 123-125. 324 
22. Le BM, Demertzis LM, Wu G, Tibbets RJ, Buller R, Arens MQ, et al. Clinical and 325 
epidemiologic characterization of WU polyomavirus infection, St. Louis, Missouri. 326 
Emerg Infect Dis. 2007; 13: 1936-1938. 327 
23. Porrovecchio R, Babakir-Mina M, Rapanotti MC, Arcese W, Perno CF, Ciotti M. 328 
Monitoring of KI and WU polyomaviruses in hematopoietic stem cell transplant 329 
patients. J Med Virol. 85: 1122-1124. 330 
24. Siebrasse EA, Nguyen NL, Smith C, Simmonds P, Wang D. Immunohistochemical 331 
detection of KI polyomavirus in lung and spleen. Virology. 2014; 468-470C: 178-184. 332 
 333 
 334 
